Springer Nature
Browse
12885_2019_5402_MOESM7_ESM.pdf (196.17 kB)

Additional file 7: of The neoepitope landscape of breast cancer: implications for immunotherapy

Download (196.17 kB)
journal contribution
posted on 2019-03-04, 05:00 authored by Pooja Narang, Meixuan Chen, Amit Sharma, Karen Anderson, Melissa Wilson
Figure S5. Expressed neoepitopes (FPKM≥5) in subtypes of breast cancer. The range of expressed neoepitopes (with FPKM≥5) is highest for the TNBC, followed by HER-2(+); and lowest for the ER/PR(+)HER-2(−) subtype of breast cancer. The median and range of the number of expressed neoepitopes are: 4 (0–131) in ER/PR(+)HER-2(−), 3 (0–82) in HER-2(+) and 8 (0–230) in TNBC. The number of samples in each case are: 583 (ER/PR(+)HER-2(−)), 138 (HER-2(+)), 92 (TNBC). Significant differences between reported FPKM values are computed pairwise for each breast cancer subtype using a Wilcox rank sum test, *** P < 0.001 (PDF 196 kb)

Funding

Breast Cancer Research Foundation

History